Yale University researchers have received a $3.5 million grant from the National Institutes of Health to fund a study of hepatitis C virus. a deadly pathogen that attacks the liver and afflicts about 170 million people worldwide.
The New Haven university said the scientists will study the molecular underpinnings of the hepatitis C virus. The researchers are Anna Marie Pyle, the William Edward Gilbert Professor of Molecular Biophysics and Biochemistry and an investigator for the Howard Hughes Medical Institute, and Brett Lindenbach, assistant professor of microbial pathogenesis.
The research will involve dissecting the critical features of viral replication in hopes of laying the groundwork for a new generation of therapies.
Hepatitis C is a pathogen that impacts the liver and afflicts 170 million people, including 2 percent of the U.S. population.
Several biotech firms built using Yale technology have been in the news in recent weeks. Mira Dx Inc., a New Haven startup that is making gene-based lab tests for disease susceptibility and response to various therapies, took in a $4 million Series A round of funding, including $1 million from Connecticut Innovations. CGI Pharmaceuticals Inc., a small-molecule-focused biotech in Branford, Conn., signed a deal to be acquired by Gilead Sciences Inc. for up to $120 million. Rib-X Pharmaceuticals Inc., an antibiotics company in New Haven, raised $5.5 million of a planned $15 million offering of debt and warrants.